

August 13, 2026

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice Regarding the Recognition of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (the “Company”) announces that it recognized non-operating income, non-operating expenses, and extraordinary losses for the three months ended June 30, 2026, as described below.

1. Details of Non-operating Income

The Company recognized foreign exchange gains of 3,985 thousand yen and interest income of 939 thousand yen as non-operating income.

2. Details of Non-operating Expenses

The Company recognized costs related to the issuance of share acquisition rights of 1,572 thousand yen and share issuance costs of 756 thousand yen as non-operating expenses.

3. Details of Extraordinary Losses

The Company recognized an impairment loss of 516 thousand yen on its fixed assets as an extraordinary loss in accordance with the Accounting Standard for Impairment of Fixed Assets.

4. Impact on Financial Results

The above items are reflected in the “Non-consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)” announced today.